ASCO 2024: Avelumab as Neoadjuvant Therapy in Patients with Muscle-Invasive Urothelial Carcinoma: Survival Data of AURA Trial, Oncodistinct 004

ASCO 2024, Muscle-Invasive Urothelial Carcinoma, Muscle invasive bladder cancer (MIBC), Avelumab, Avelumab as Neoadjuvant Therapy, AURA Trial, Oncodistinct 004.

Related Keywords

Brussels ,Bruxelles Capitale ,Belgium ,Bruxelles ,United States ,Chicago ,Illinois ,Toronto ,Ontario ,Canada ,American ,Institut Jules Bordet ,Jeremy Blanc ,University Of Toronto ,Twitter ,Society Of Urologic Oncology ,American Society Of Clinical Oncology ,Clinical Oncology ,Annual Meeting ,Universitaire De Bruxelles ,Libre De Bruxelles ,Rashid Sayyid ,Urologic Oncology ,Clinical Fellow ,Neoadjuvant Therapy Before Radical Cystectomy ,